ID S1189

Human gene therapy products for infectious diseases cannot be distributed, sold, or administered in Idaho unless the manufacturer waives immunity from lawsuits for design defect injuries

Manufacturers that distribute such products in Idaho are automatically deemed to have waived federal immunity protections under 42 U.S.C. 300aa-1 (the National Childhood Vaccine Injury Act)

"Human gene therapy product" is defined to include nucleic acids (plasmids, RNA), genetically modified microorganisms (viruses, bacteria, fungi), genome editing tools, and ex vivo genetically modified human cells

Declared an emergency measure with an effective date of July 1, 2025